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Renal cell carcinomas (RCC), mostly occurring in adults aged 60e70 years, can result from well-known
factors like cigarette smoking, obesity and hypertension. However, they have been associated with
genetic alterations in children and young adults. A 28 year-old male patient with a conﬁrmed RCC un-
derwent biomolecular and immunohistochemical analyses due to his young age. A point mutation of the
von Hippel-Lindau tumor suppressor gene was identiﬁed. Young patients under 40 years with diagnosed
RCC should undergo additional diagnostic investigation, hence the discovery of an underlying cause. This
could be important for further treatment and counseling of these young patients.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction Focused biomolecular and immunohistochemical analyses wereRenal cell carcinomas (RCC) mostly occur in adults aged 60e
70 years and are rare in children and young adults. They can result
from well-known factors like cigarette smoking, obesity and hy-
pertension in older patients and have been recently associated with
genetic alterations in children and young adults.1 We report and
discuss our ﬁndings of a 28 year-old men in whom a RCC was
diagnosed.Case presentation
A 28 year-old Caucasian man with a renal mass in the inter-
mediate ventral part close to the hilum of the right kidney
underwent surgery without intraoperative or postoperative com-
plications. Histological examination conﬁrmed a 1.5 cm clear cell
RCC (ccRCC, Fig. 1A) without inﬁltration of the renal capsule, i.e.
TNM classiﬁcation was pT1a, cN0, cM0, Fuhrman grade 2, R0.ntonal Hospital Aarau, Tell-
4 80; fax: þ41 62 838 47 53.
).
Inc. This is an open access article uperformed to search for potential underlying genetic alterations.
Overexpression of transcription factor E3 (TFE3) (Fig. 1B) and
transcription factor EB (TFEB) (Fig. 1C) for the translocation Xp11.2
as well as ﬂuorescent in situ hybridization (FISH) tests for chro-
mosomes 3 (3p11.1-q11.1), 7 (7p11.1-q11.1), 17 (17p11.1-q11.1), and
deletion of chromosome 9 (9p21) were negative. Mutation analysis
of the von Hippel-Lindau (VHL) tumor suppressor gene on chro-
mosome 3 (3p25.3) revealed a point mutation of the Exon 1 (Fig. 2).
After more than 48 months, the patient had an uneventful
follow-up without any relapse of the ccRCC. Furthermore, renal
function was preserved with normal levels of serum creatinine and
creatinine clearance.Discussion
RCC is rare in patients under 40 years of age. Due to usage of
ultrasound and computed tomography (CT), an increasing number
of RCCs are discovered incidentally.1 These RCCs are at presentation
smaller and at lower stage.1 Partial nephrectomy (PN) is the treat-
ment of choice for localized T1a tumors over radical nephrectomy
(RN) (grade of recommendation, GR: A; level of evidence, LE: 1b).1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. A: Hematoxylin and eosin (HE) stain: Clear cell renal cell carcinoma with tubular and solid aggregates of large tumor cells with ample clear cytoplasm, monomorphous
vesicular nuclei and inconspicuous nucleoli (magniﬁcation 20). B: Negative immune-reactivity for transcription factor E3 (magniﬁcation 20). C: Negative immune-reactivity for
transcription factor EB (magniﬁcation 20).
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removed. RCCs are most likely to occur in adults aged 60e70 years
and mainly result fromwell-known etiological factors (LE: 2a) such
as cigarette smoking, obesity and hypertension.1 Presentation in
children and young adults is rare and often associated with genetic
alterations (e.g. VHL disease or Xp11.2 translocation).1,2 Therefore,
additional diagnostic investigations on the renal specimens were
carried out.
A point mutation of the VHL tumor suppressor gene on chro-
mosome 3 (3p25.3) was detected upon further evaluation in thisFigure 2. Gene sequence analysis: Red line indicating the point mutation (G to T) on
nucleotide 810, resulting in a stop codon for transcription and loss of function of the
von Hippel-Lindau tumor suppressor gene.patient, hence a “loss-of-function mutation.”1,3 De novo mutations
are found in 20%, while VHL mutations are inherited in 80%.4 The
autosomal dominant genetic disease usually presents with clinical
manifestations within the second and fourth decade of life.3 In re-
gard to RCC, the mean age is 39 years at presentation in patients
with VHL disease, which is approximately 20 years earlier than for
sporadic RCC.3 In addition to the young age of presentation, RCC
associated with VHL disease also recurs more frequently.3
The VHL disease is also associated with other neoplasms such
as phenochromocytoma, neuroendocrine tumor, pancreatic cyst,
and endolymphatic sac tumor. Therefore, patients should undergo
physical and radiologic investigations. In our patient no
other suspicious lesion was detected and family history was
inconspicuous.
To emphasize the importance of this matter, patients with VHL
disease succumb early, i.e. median age of 49 years and a third of
whom die from metastatic RCC.3
Therefore, patients should be counseled with regard to genetic
analysis whether the VHL disease is present or not. Knowing
whether one is carrying an underlying hereditary disease or not is
crucial as it concerns not only patients, but also their children. It has
been demonstrated that clinical screening of children at risk of VHL
disease can detect tumors before the ﬁrst symptoms become
apparent and reducemorbidityconsequently.5 Therefore, if a genetic
alteration such as the VHL disease is missed, not only the life of this
patient is in jeopardy but the prosperity of the entire family.
Our patient underwent regular, yet uneventful follow-up, as
neither local recurrence nor metastatic progression occurred.
Unilateral recurrence rate and bilateral appearance of RCC are
high in patients with VHL disease.3 Therefore, regular follow-up is
warranted for each patient with VHL tumor suppressor gene
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into metastatic disease. Usually, patients are under close surveil-
lance using imaging techniques such as CT or magnetic resonance
imaging. In the unfortunate situation when metastases are detec-
ted, targeting agents, e.g. Sorafenib, should be considered for
treatment, as neoangiogenesis resulting from an overexpression of
vascular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF) is promoted by hypoxia-induced factor
(HIF) accumulation in patients with VHL-Gene mutation.1
Conclusion
Patients younger than 40 years of age with diagnosed RCC,
additional diagnostic work up should be offered for exploration of
potential underlying conditions such as VHL tumor suppressor gene
mutation could be identiﬁed.
In case of an underlying condition such as the VHL disease,
tailored treatment should be initiated to preserve renal function as
long and as much as possible, and to limit cancer progression or
relapse. Furthermore, patients at risk of carrying a hereditary dis-
ease must be informed and counseled accordingly.
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